Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RJK-RT2831 in hematologic malignancies
NCT06756451Phase 1Recruiting
- Sponsor
- Nanjing RegeneCore Biotech Co., Ltd.
- Start
- Mar 2025
- Primary completion
- Apr 2028
- Modality
- Bispecific Antibodies, Nanobodies (VHH)
- Countries
- 1
01
Overview
Phase 1, open-label trial of RJK-RT2831 in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS), sponsored by Nanjing RegeneCore Biotech Co., Ltd. Primary endpoints: Adverse Events, Maximum Tolerated Dose at 28 days and 2 more. Started Mar 2025; status: recruiting.
02
Drugs
RJK-RT2831
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT06756451.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06756451.